Last reviewed · How we verify
Bavencio
Bavencio is a Small molecule drug developed by Pfizer. It is currently in discontinued development for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma, Renal cell carcinoma. Also known as: Avelumab as prescribed in the real world, Avelumab.
At a glance
| Generic name | Bavencio |
|---|---|
| Also known as | Avelumab as prescribed in the real world, Avelumab |
| Sponsor | Pfizer |
| Target | Programmed cell death 1 ligand 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
- Merkel cell carcinoma
- Renal cell carcinoma
Common side effects
Key clinical trials
- An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhib (Phase 1)
- AN OPEN LABEL, SINGLE ARM PHASE 1B STUDY OF AVELUMAB PLUS AXITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (Phase 1)
- Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma (Phase 2)
- A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer (Phase 1)
- A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Phase 1)
- A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer (Phase 2)
- A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-ba (Phase 2)
- A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced Solid Tumors Who Have Progressed During or (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bavencio CI brief — competitive landscape report
- Bavencio updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Bavencio
What is Bavencio?
Bavencio is a Small molecule drug developed by Pfizer, indicated for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma, Renal cell carcinoma.
What is Bavencio used for?
Bavencio is indicated for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma, Renal cell carcinoma.
Who makes Bavencio?
Bavencio is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
Is Bavencio also known as anything else?
Bavencio is also known as Avelumab as prescribed in the real world, Avelumab.
What development phase is Bavencio in?
Bavencio is in discontinued.
What does Bavencio target?
Bavencio targets Programmed cell death 1 ligand 1.
Related
- Target: All drugs targeting Programmed cell death 1 ligand 1
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
- Indication: Drugs for Merkel cell carcinoma
- Indication: Drugs for Renal cell carcinoma
- Also known as: Avelumab as prescribed in the real world, Avelumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing